Endometriosis, Adenomyosis, and Fertility: A Specialist's Deep Dive into Diagnosis, Treatment, and Reproductive Aging
Peter Attia and a Brazilian reproductive medicine specialist explore endometriosis and adenomyosis—two chronic, estrogen-driven uterine conditions affecting hundreds of millions of women—and trace how delayed diagnosis, hormonal resistance, and modern menstrual patterns worsen outcomes. The conversation then shifts to fertility: how age-driven aneuploid rates follow a J-curve, when surgery or IVF is the right call, and what frontier technologies like GnRH agonists, mitochondrial replacement, ovarian transplantation, and stem-cell-derived oocytes may offer in the coming decade.
Overview
Peter Attia opens with his guest, a São Paulo–based reproductive medicine specialist, by framing endometriosis as a chronic disease where endometrial-like tissue grows outside the uterus, affecting roughly 10% of reproductive-age women globally—about 200 million—while 30–50% of infertile women carry the diagnosis. The guest explains that adenomyosis, often called the 'missed disease,' may be even more prevalent at 20–30%, and up to 70% of endometriosis patients also have it.
A central mechanistic point is that endometriotic lesions upregulate aromatase and produce their own estrogen, while simultaneously exhibiting progesterone resistance, allowing them to behave like low-grade tumors—harboring oncogenic somatic mutations yet remaining benign due to surrounding fibrosis. Modern women accumulate roughly four times as many ovulatory cycles as women 200 years ago (400 vs. 100), likely driving rising prevalence. Diagnosis is delayed 5–12 years on average because of cultural normalization of female pain, lack of simple biomarkers, and historic reliance on invasive laparoscopy; the conversation details a three-tier ultrasound protocol and MRI as superior non-invasive alternatives.
Treatment depends on reproductive intent: for women not trying to conceive, progestins, the Mirena IUD, or combined oral contraceptives manage symptoms; for those pursuing fertility, the algorithm weighs timing surgery (excision of endometriomas, adhesiolysis) against proceeding directly to IVF, always mindful that cystectomy can reduce AMH by 40–50%. The guest introduces the J-curve of aneuploid rates—roughly 25% at age 25, jumping to 60% at 38 and 80% by 42—to underscore that age is the single most important fertility variable, even above endometriosis burden.
For adenomyosis patients with failed IVF transfers, a 2–4-month course of GnRH agonists before frozen embryo transfer substantially improves implantation rates and reduces miscarriage risk. The episode closes with frontier topics—mitochondrial replacement therapy, ovarian cortex transplantation, and stem-cell-derived oocytes—and excitement about HMI115, a monoclonal antibody in Phase 3 trials targeting the prolactin receptor as the first potential non-hormonal biologic for endometriosis.
Key quotes
5It's like putting a 1,000 horsepower F1 engine into a golf cart—you just have the machinery, but you can't go further.
Imagine the endometriosis lesion is a burglar. Surgery can remove the burglar. Hormones can lock the door. But once you have this alarm system ringing year after year, the wiring changed—and now even a wind triggers the alarm.
Age is the most important factor—and even doctors don't realize it, because sometimes you see them trying to conceive naturally at 42.
Reproduction in humans is very inefficient. You lose a thousand eggs every month, just to ovulate one—and you need one year to even call it infertility.
We're not going to take no for an answer. We're going to get these diagnoses so we can start the treatment—because the earlier you start, the better the prognosis.
Key ideas
9Endometriosis affects 200 million women worldwide
Approximately 10% of reproductive-age women globally have endometriosis. Among women struggling with infertility, the prevalence rises to 30–50%, and having endometriosis confers roughly a 40% chance of being infertile.
Modern women experience four times as many cycles as ancestors
Two hundred years ago, women averaged around 100 ovulatory cycles in a lifetime (later menarche, multiple pregnancies, prolonged breastfeeding). Today that figure is closer to 400. Each cycle drives retrograde menstruation, the likely primary mechanism for endometriosis, suggesting modern lifestyle—not purely genetics—is increasing prevalence.
Endometriotic lesions fuel themselves with estrogen
Lesions upregulate aromatase, producing their own estrogen locally. Combined with progesterone receptor downregulation (progesterone resistance), this means simply suppressing ovarian estrogen is insufficient to stop disease progression, mirroring the way tumors can bypass systemic hormonal controls.
Adenomyosis: the more prevalent, underdiagnosed sibling
Adenomyosis (endometrial tissue within the myometrium) may affect 20–30% of women—more than endometriosis—yet receives far less attention. Up to 70% of endometriosis patients also have adenomyosis, and it is adenomyosis, not endometriosis per se, that most impairs implantation and raises miscarriage risk via junctional-zone contractions.
Three distinct pain mechanisms require different treatments
Nociceptive pain (from the lesion itself) responds to hormonal therapy and surgery. Neuropathic pain (nerve infiltration by lesions) may need gabapentin or SNRIs and nerve-sparing excision. Nociplastic pain (central sensitization after years of untreated disease) does not resolve with surgery alone and requires pelvic-floor physiotherapy and pain-specialist referral.
Diagnosis is delayed 5–12 years on average
Cultural normalization of female pain, the absence of a simple blood biomarker, and historic reliance on diagnostic laparoscopy create a diagnostic gap of five to twelve years in most countries (roughly six years in the US). The 2025 ACOG guidance now permits clinical diagnosis and empirical treatment without surgery.
Aneuploid rates follow a J-curve, not a straight line
Egg aneuploidy is surprisingly high even at young ages (roughly 20–25% at age 25), dips to a sweet spot around age 25–28, then rises sharply: ~35% at 31, ~40% at 35, ~60% at 38, and ~80% by the early 40s. This J-curve means reproductive delay carries compounding, non-linear cost—a fact many clinicians and patients underappreciate.
Endometrioma cystectomy reduces ovarian reserve by up to 50%
Endometriomas are pseudo-cysts tightly adherent to the ovarian cortex where primordial follicles reside. Stripping them during surgery co-removes healthy follicular tissue, dropping AMH by 40–50%. The Fenton reaction within the cyst also produces hydroxyl radicals toxic to oocyte DNA, causing follicular burnout even before surgery—so egg retrieval should precede cystectomy.
HMI115: the first potential non-hormonal biologic for endometriosis
Endometriotic lesions express prolactin receptors. HMI115, an anti-prolactin-receptor monoclonal antibody, is currently in Phase 3 trials and has shown reduced pain and slower disease progression without hormonal suppression—a potential paradigm shift away from decades of ovulation-blocking as the only systemic option.
Practical takeaways
7- 1
Demand early diagnosis—don't wait years 27:55
ACOG now permits clinical diagnosis based on symptoms alone (no laparoscopy needed). If you have cyclic pelvic pain, painful intercourse, or bowel symptoms, push for specialist evaluation rather than accepting 'normal period pain' as an answer.
- 2
A normal standard ultrasound does not rule out endometriosis 38:56
Standard transvaginal ultrasound has low sensitivity for endometriosis. Request either an MRI or a dedicated specialist ultrasound protocol with bowel prep, which approaches 95–98% sensitivity and specificity.
- 3
Post-surgical hormone suppression cuts recurrence by 88% 53:00
Inserting a Mirena IUD after endometriosis excision reduces recurrence risk by roughly 88% versus placebo. Always pair surgery with a suppression strategy; treating surgery as a standalone cure is one of the most common clinical mistakes.
- 4
For adenomyosis and failed IVF: try GnRH agonists first 1:12:40
Two to four months of GnRH agonist (or oral GnRH antagonist) treatment before frozen embryo transfer significantly improves implantation rates and reduces miscarriage rates in women with adenomyosis, making it a critical pre-transfer step that is often skipped.
- 5
Freeze embryos before operating on endometriomas 1:24:33
Because endometrioma cystectomy can halve ovarian reserve, always prioritize IVF egg retrieval first if there is any risk to future fertility. Operate on the endometrioma afterward only if it exceeds 5–6 cm or causes significant pain.
- 6
Treat central sensitization before surgery, not after 1:23:11
Women with long-standing chronic pelvic pain likely have nociplastic (centrally sensitized) pain that surgery will not resolve. Eight weeks of pre-operative pelvic-floor physiotherapy followed by resumption post-surgery produces significantly better pain outcomes.
- 7
Egg freezing sweet spot: 32–35, not 25 1:37:08
Despite the biological advantage of freezing at 25, roughly 90% of women who freeze eggs never use them. From a cost-effectiveness standpoint, the 32–35 window balances still-good egg quality against the real probability of actually needing those eggs.
Topics & chapters
15Introduction and episode roadmap
Peter Attia welcomes his guest from São Paulo and outlines two intertwined topics: diseases of the uterus (primarily endometriosis) and infertility, with its diagnostic and treatment landscape.
Uterine anatomy and endometriosis defined
The three uterine layers—serosa, myometrium, endometrium—are explained, and endometriosis is defined as endometrial-like tissue outside the uterus (on tubes, ovaries, bowel, bladder, diaphragm), affecting 10% of reproductive women and 30–50% of infertile women.
Genetics and risk factors
Endometriosis carries about 50% heritability; a first-degree relative raises your risk sevenfold. Retrograde menstruation occurs in 90% of women but only 10% develop the disease, implicating immune dysregulation as the key differentiating factor.
The modern cycle burden: 100 vs. 400 ovulations
Historical women had roughly 100 lifetime cycles (later menarche, more pregnancies, longer breastfeeding); modern women face ~400. This four-fold increase in retrograde flow events likely drives rising endometriosis prevalence more than genetics alone.
Hormonal biology: estrogen dominance and progesterone resistance
Endometriotic lesions overexpress aromatase, self-producing estrogen, while progesterone receptors are downregulated—mirroring insulin resistance in that far more hormone is needed to achieve effect. Some lesions also carry somatic oncogenic mutations (KRAS, PIK3CA) yet remain benign due to surrounding fibrosis.
Adenomyosis: the overlooked condition
Adenomyosis—endometrial tissue invading the myometrium—may affect 20–30% of women and is increasingly seen in younger patients without prior pregnancies. It shares estrogen dependence and progesterone resistance with endometriosis but is a distinct disease with its own molecular pathway, and up to 70% of endometriosis patients also have it.
The six Ds: recognizing endometriosis symptoms
The clinical hallmarks are Dysmenorrhea, Deep dyspareunia, Dyschezia (painful bowel movements), Dysuria (painful urination), Difficulty conceiving, and Dysfunctional chronic pelvic pain. Many women normalize these symptoms or are told they are normal, contributing to the diagnosis gap.
Three layers of pain and why surgery alone fails
Nociceptive pain (direct lesion), neuropathic pain (nerve infiltration), and nociplastic pain (central sensitization) each require different interventions. Years of untreated disease rewire pain processing so that even a clean surgical pelvis can still register pain.
Diagnosing endometriosis: delays, imaging, and the new ACOG standard
The average diagnosis delay is 5–12 years. Three ultrasound tiers exist—standard (low sensitivity), augmented sliding-sign, and specialist bowel-prep protocol—alongside MRI, which excels for extra-pelvic and deep lateral lesions. The 2025 ACOG guidance allows empirical treatment on clinical grounds alone.
Treatment framework: medical first, surgery second
For women not seeking conception, first-line options include combined oral contraceptives, progestin-only pills (dienogest, norindone), or the Mirena IUD. Surgery (laparoscopic excision) is reserved for medication failure or specific indications. All patients should be managed as having a chronic, lifelong disease—not a one-time surgical fix.
Fertility and the J-curve of aneuploid rates
Aneuploidy rates follow a J-curve: roughly 20–25% at age 25, rising to 35% at 31, 40% at 35, 60% at 38, and 80%+ in the early 40s. Age—not endometriosis burden—is the single most important fertility variable, and the efficiency of human reproduction is inherently low even at peak fertility.
Adenomyosis and failed IVF: GnRH suppression before transfer
Unlike endometriosis, adenomyosis impairs pregnancy maintenance via junctional-zone contractions that expel embryos at 6–8 weeks. Two to four months of GnRH agonist (e.g., Lupron/goserelin) or oral antagonist (elagolix, relugolix) before frozen embryo transfer significantly improves live-birth rates.
Surgical pitfalls: central sensitization, cystectomy, and damaged tubes
Three key surgical mistakes: operating on centrally sensitized pain without pre/post pelvic physiotherapy; stripping endometriomas and halving AMH when fertility matters; leaving hydrosalpinx tubes in place (they reduce IVF success by 50% via embryotoxic cytokines).
Egg freezing: economics, real-world use, and optimal timing
Only about 10% of women who freeze eggs ever return to use them. At ~$5,000 per cycle in Brazil (similar ranges globally), the cost-effectiveness sweet spot is 32–35, not 25—biologically earlier is better, but the probability of needing those eggs peaks at a later age.
Frontier technologies and a call to action
Mitochondrial replacement therapy addresses only cytoplasmic (not chromosomal) aging; ovarian cortex transplantation can postpone menopause 10–15 years but lacks fertility outcome data; stem-cell-derived oocytes are roughly 10 years away. HMI115 (anti-prolactin receptor monoclonal antibody, Phase 3) may become the first non-hormonal biologic for endometriosis. The episode closes urging patients to demand specialist imaging and early treatment.